Pacific Shuanglin Bio-pharmacy Co., LTD (SHE:000403)

China flag China · Delayed Price · Currency is CNY
22.15
+0.04 (0.18%)
May 30, 2025, 2:45 PM CST
-16.82%
Market Cap 16.18B
Revenue (ttm) 2.59B
Net Income (ttm) 712.46M
Shares Out 731.07M
EPS (ttm) 0.97
PE Ratio 22.89
Forward PE 14.10
Dividend 0.50 (2.26%)
Ex-Dividend Date Jun 4, 2025
Volume 8,314,477
Average Volume 8,505,328
Open 21.58
Previous Close 22.11
Day's Range 21.58 - 22.35
52-Week Range 19.46 - 29.92
Beta 0.76
RSI 52.51
Earnings Date Aug 28, 2025

About SHE:000403

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation. The c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 2,635
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 000403
Full Company Profile

Financial Performance

In 2024, SHE:000403's revenue was 2.65 billion, an increase of 14.00% compared to the previous year's 2.33 billion. Earnings were 745.32 million, an increase of 21.76%.

Financial Statements

News

There is no news available yet.